Merck & Co. Inc. buy Finanzgonzo
Start price
28.07.11
/
50%
€24.30
Target price
09.01.12
€30.00
Performance (%)
26.55%
End price
09.01.12
€30.16
Summary
This prediction ended on 09.01.12 with a price of €30.16. The BUY prediction by Finanzgonzo finished with a performance of 26.55%. Finanzgonzo has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Merck & Co. Inc. | -1.961% | -1.961% | 1.937% | 43.308% |
iShares Core DAX® | -1.114% | 5.062% | 24.922% | 25.215% |
iShares Nasdaq 100 | 1.816% | 9.828% | 29.548% | 44.324% |
iShares Nikkei 225® | 2.113% | 8.218% | 22.231% | 12.395% |
iShares S&P 500 | 2.038% | 7.448% | 30.358% | 43.899% |
Comments by Finanzgonzo for this prediction
In the thread Merck & Co. Inc. diskutieren
zulassung für victrelis in europa
Merck & Co hat die Zulassung für das Hepatitis C - Medikament Victrelis von der Europäischen Kommission erhalten. Kooperation mit Roche.
Quelle: Der Aktionär Nr. 31 / 2011
(Vom Mitglied beendet)